- Home
- NPCT vs AQST Comparison
NPCT vs AQST Comparison
Compare NPCT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- AQST
- Stock Information
- Founded
- NPCT 2020
- AQST 2004
- Country
- NPCT United States
- AQST United States
- Employees
- NPCT N/A
- AQST N/A
- Industry
- NPCT Investment Managers
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- NPCT Finance
- AQST Health Care
- Exchange
- NPCT Nasdaq
- AQST Nasdaq
- Market Cap
- NPCT 284.1M
- AQST 254.1M
- IPO Year
- NPCT N/A
- AQST 2018
- Fundamental
- Price
- NPCT $10.37
- AQST $2.76
- Analyst Decision
- NPCT
- AQST Strong Buy
- Analyst Count
- NPCT 0
- AQST 5
- Target Price
- NPCT N/A
- AQST $11.40
- AVG Volume (30 Days)
- NPCT 107.1K
- AQST 984.2K
- Earning Date
- NPCT 01-01-0001
- AQST 05-12-2025
- Dividend Yield
- NPCT 9.82%
- AQST N/A
- EPS Growth
- NPCT N/A
- AQST N/A
- EPS
- NPCT N/A
- AQST N/A
- Revenue
- NPCT N/A
- AQST $57,561,000.00
- Revenue This Year
- NPCT N/A
- AQST N/A
- Revenue Next Year
- NPCT N/A
- AQST $39.51
- P/E Ratio
- NPCT N/A
- AQST N/A
- Revenue Growth
- NPCT N/A
- AQST 13.79
- 52 Week Low
- NPCT $8.58
- AQST $2.20
- 52 Week High
- NPCT $10.63
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- NPCT 56.04
- AQST 48.51
- Support Level
- NPCT $10.20
- AQST $2.65
- Resistance Level
- NPCT $10.43
- AQST $3.05
- Average True Range (ATR)
- NPCT 0.12
- AQST 0.16
- MACD
- NPCT 0.05
- AQST 0.00
- Stochastic Oscillator
- NPCT 90.00
- AQST 50.51
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.